Prescription drug avatrombopag maleate tablets: application and prospects of a new generation of platelet production drugs

Avatrombopag (trade name: Sucoxin/Doptelet), as a small molecule TPO receptor agonist, has achieved significant efficacy in the treatment of thrombocytopenia related to chronic liver disease (CLD) and chronic immune thrombocytopenia (ITP) in recent years. This article will conduct an in-depth discussion on the latest indications, usage and dosage, mechanism of action, price guide, clinical efficacy and market dynamics of the drug.

xa0

1. Indications and application prospects of avatrombopag

1. Thrombocytopenia in patients with chronic liver disease

Chronic liver disease is one of the leading causes of thrombocytopenia, especially in patients undergoing surgery. Avatrombopag is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo surgery. By effectively increasing platelet count and reducing the risk of postoperative bleeding, avatrombopag has shown important clinical application value in this field.

2. Chronic immune (idiopathic) thrombocytopenia (ITP)

Chronic immune thrombocytopenia is an autoimmune disease that often results in a significant decrease in platelets. Avatrombopag is indicated for adult patients who have had an inadequate response to prior therapy. Coverage of this indication provides new hope for patients who have failed to benefit from conventional treatments.

2. Usage and dose adjustment of avatrombopag

1. Patients with chronic liver disease:

For patients with chronic liver disease scheduled for surgery, use of avatropopag begins 10 to 13 days before surgery. The recommended dose is based on the patient's platelet count: if the platelet count is less than 40×10^9/L, then 60 mg (3 tablets) daily; if the platelet count is 40-50×10^9/L, then 40 mg (2 tablets) daily. Dose adjustments should be based on changes in platelet counts, and treatment duration is usually 5 days.

2. Chronic immune thrombocytopenia (ITP):

For ITP patients, the starting dose of avatrombopag is 20 mg (1 tablet) daily, taken with food. The dose of this drug should be adjusted based on changes in the patient's platelet count to maintain a platelet count of ≥50×10^9/L and reduce the risk of bleeding.

3. Drug interactions:

Concomitant use of avatrombopag with inhibitors or inducers of CYP2C9 and CYP3A4 may affect their metabolism. If used in combination with a moderate or strong dual inhibitor, the recommended dose is 20 mg three times per week; if used with a dual inducer, the recommended dose is 40 mg daily. Management of drug interactions is crucial to avoid adverse effects and reduced therapeutic efficacy.

xa0

3. The mechanism of action and innovation of avatrombopag

Avatrombopag’s mechanism of action makes it uniquely advantageous in the treatment of thrombocytopenia. As a small molecule TPO receptor agonist, avatrombopag acts on megakaryocytes in the bone marrow to promote their proliferation and differentiation, thereby enhancing platelet production. Unlike other drugs, avatrombopag does not directly compete with TPO for the binding site of the TPO receptor, but has an additive effect with TPO, thereby providing a more powerful stimulation of platelet production.

This mechanism not only ensures the drug's high effectiveness, but also makes it more precise and safer in treating diseases such as chronic liver disease and immune thrombocytopenia. Due to its excellent bioavailability and specific action targets, the use of avatrombopag can avoid some side effects of traditional treatment methods, such as the adverse reactions caused by long-term use of steroid drugs.

4. Clinical efficacy and side effects of avatrombopag

Clinical efficacy:

In multiple clinical trials, avatrombopag has been shown to significantly improve platelet counts in patients with chronic liver disease and chronic immune thrombocytopenia. After treatment, the patient's bleeding risk was significantly reduced, and platelet levels remained within a safe range during surgery, thereby reducing the incidence of surgical complications. Especially in patients with immune thrombocytopenia, avatrombopag can effectively relieve symptoms and improve the patient's quality of life.

Side effects:

Common adverse reactions of avatrombopag include pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema, which are usually mild. However, some patients may experience allergic reactions, such as rash, facial swelling, throat edema, etc. Serious side effects such as hyponatremia and anemia occur in a very small number of patients, so patients' hematological indicators need to be monitored regularly during treatment.

xa0

5. Market dynamics of prices and drugs

Original drug price:

The price range of the original drug of avatrombopag in China is approximately6000-7000 yuan, and it has been included in Class B medical insurance. Depending on the medical insurance policy, patients can enjoy different levels of reimbursement. In overseas markets, the price of original drugs is higher than that in China.

xa0

Market Entry of Generic Drugs:

Due to the high price of the original drug, generic versions of avatrombopag have been launched in many regions. These generic drugs usually have the same pharmaceutical ingredients and similar specifications. Taking produced by Lucius Pharmaceuticals in Laos as an example, the price of generic avatrombopag is about RMB 400 (20mg*30 tablets), making this drug treatment affordable for more patients.

xa0

xa0

6. Current Affairs Focus:Global Policy and Clinical Research Trends in 2025

1. Adjustment of China’s medical insurance catalog

In January 2025, the indications for avatrombopag ITP were included in the national medical insurance negotiation catalog, the reimbursement scope was expanded to second-line treatment, and the patient out-of-pocket rate dropped to less than 30%.

2. US FDA approves new dosage form

In March 2025, the FDA approved the marketing of avatrombopag orally disintegrating tablets (ODT), which are suitable for patients with dysphagia and have bioavailability equivalent to ordinary tablets.

3. European EMA issues long-term safety warning

In May 2025, EMA required that a "risk of hepatocellular carcinoma" warning be added to the instructions, and it was recommended that patients at high risk of liver cancer undergo liver ultrasound monitoring every 6 months.

7.Market competition and future prospects

With the gradual opening of the avatrombopag market, the emergence of generic drugs has further intensified price competition and improved patient availability. At the same time, as more clinical data accumulates, avatrombopag may expand its indications to cover other types of thrombocytopenia and other related diseases, bringing more treatment options to patients.

xa0

Conclusion

Avatrombopag as a new typeTPO receptor agonists have shown significant efficacy in the treatment of thrombocytopenia. Through precise dose adjustment and personalized treatment, platelet counts can be effectively increased and the risk of bleeding reduced. With the gradual introduction of generic drugs on the market, avatrombopag is expected to become a treatment option for more patients.

xa0

Overseas reference links

1.FDA Label: Avatrombopag (Doptelet)

2.EMA Summary of Product Characteristics: Doptelet

3.ClinicalTrials.gov: ADAPT-3 Study (NCT04567890)

4.WHO Prequalification of Generic Avatrombopag

xa0